Novo­cure fails PhI­II in plat­inum-re­sis­tant ovar­i­an can­cer

Novo­cure’s ovar­i­an can­cer treat­ment failed to meet the pri­ma­ry end­point of over­all sur­vival in a Phase III tri­al, send­ing the New Jer­sey biotech’s stock price down 32% on Mon­day morn­ing.

Novo­cure said Mon­day that a com­bi­na­tion of its tu­mor treat­ing field ther­a­py, called TTFields, and the chemother­a­py pa­cli­tax­el did not meet the pri­ma­ry end­point of over­all sur­vival in pa­tients who have un­der­gone mul­ti­ple lines of treat­ment in ovar­i­an can­cer and are re­sis­tant to plat­inum-based treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER